FIT BIOTECH OY
COMPANY RELEASE 4 July 2016 at 10.00 EET
FIT BIOTECH PROMOTES LIISA LAITINEN TO SENIOR VICE PRESIDENT
AND CHIEF FINANCIAL OFFICER
FIT Biotech Oy announced today the promotion of Liisa Laitinen to Senior Vice President and CFO responsible for finance and administration. Ms. Laitinen will also have responsibility for managing FIT's operations in Tampere including the GMP-manufacturing facility. Ms. Laitinen will report to FIT's CEO, James Kuo, MD, MBA, based in La Jolla, California. She was previously employed in international business in Finland and abroad, working with corporations like Paloheimo, Dresdner Bank and Bank of America.
"Liisa has been a key part of our success and we are excited to promote her to this new role. She joined the company in 2000 as Coordinator of Administration and quickly rose to become VP, Finance and Administration in 2003. Her experience as an integral member of the management team coupled with her leadership skills will enable us to fulfill our mis- sion to develop gene-based treatments and gene vaccines based on our proprietary GTU®- vector technology, " said James Kuo, CEO of FIT.
CEO, FIT Biotech Oy
Tel: +358 44 0331307, USA: +1 858 220 5703
Certified Advisor: Translink Corporate Finance Oy, telephone +358 20 743 2790
FIT Biotech Oy in brief
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented Gene Transport Unit vector technologies (GTU®; gtGTU®) for new-generation medical treatments. FIT Biotech's gene transport technologies meet a significant medical challenge in the usability of gene based treatments and therapeutic DNA vaccines. FIT Biotech applies and develops the vector technologies in its drug development programmes. Examples of application areas include cancer (gene based treatments), infectious diseases such as HIV and tuberculosis, and animal vaccines.
FIT Biotech shares are listed on the First North Finland market maintained by Nasdaq OMX Helsinki Oy. The trading code of the company is FITBIO.